logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO-GU 2019—Pembrolizumab+axitinib better than sunitinib in advanced or metastatic clear-cell RCC

KEYNOTE-426 supports first-line treatment with pembrolizumab+axitinib as a new standard of care.